# Romidepsin Plus 3BNC117 Phase 2a Study

> **NCT02850016** · PHASE2 · COMPLETED · sponsor: **Rockefeller University** · enrollment: 48 (actual)

## Conditions studied

- Human Immunodeficiency Virus (HIV)

## Interventions

- **DRUG:** 3BNC117
- **DRUG:** Romidepsin

## Key facts

- **NCT ID:** NCT02850016
- **Lead sponsor:** Rockefeller University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-06
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2022-07-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02850016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02850016, "Romidepsin Plus 3BNC117 Phase 2a Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02850016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*